A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.

Trial Details

NCT ID

NCT06939595

Phase

PHASE3

Sponsor

Celltrion

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

CT-P51
EU-approved Keytruda

Locations (sample)

Tbilisi, Georgia|41.69143,44.83412

Key Eligibility Criteria

Stage IV, non squamous NSCLC
Have not received any prior systemic anti-cancer therapy for metastatic NSCLC
Have at least 1 measurable lesion per RECIST version 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →